Fabry disease is a rare X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (GLA), encoded by the GLA gene at locus Xq22.1. Classic loss-of-function mutations result in absent or near-absent enzyme activity, while late-onset variants retain partial activity — a distinction with direct therapeutic implications documented by Desnick RJ et al. (2021) in their genotype-phenotype analysis.

The primary pathogenic substrates are globotriaosylceramide (Gb3) and its deacylated form globotriaosylsphingosine (lyso-Gb3), which accumulate in vascular endothelium, renal tubular cells, cardiomyocytes, and neurons, causing progressive morbidity from renal, cardiac, and neurological complications. Protalix's patents — including WO2021229576A1 — specifically cite Gb3 and lyso-Gb3 in plasma, urine, and tissues as mechanistic biomarker endpoints.

An upstream biosynthetic vulnerability is also being targeted: glucosylceramide synthase (GCS) inhibition, covered in Idorsia Pharmaceuticals' substrate reduction therapy patent (US20220233717A1), blocks glycosphingolipid production irrespective of GLA genotype — representing a mutation-agnostic therapeutic approach. The NIH GeneReviews resource provides foundational genotype guidance for clinicians navigating these modalities.

Null or severe GLA mutations eliminate enzymatic capacity and require systemic enzyme restoration via ERT or gene therapy, while amenable missense mutations producing unstable but structurally intact protein can be targeted by pharmacological chaperones. This genotype stratification directly defines the competitive boundaries between therapeutic modalities in this market.

Long-term registry data from Wanner C et al. (2021) confirms that both agalsidase alfa and agalsidase beta stabilize or slow kidney function decline and cardiac hypertrophy in classic Fabry disease, with earlier ERT initiation associated with better outcomes. This real-world evidence base supports the case for prompt diagnosis and treatment initiation — a dynamic that benefits all ERT market participants including pegunigalsidase alfa.

The BALANCE trial's head-to-head design — pegunigalsidase alfa 1 mg/kg biweekly versus agalsidase beta 1 mg/kg biweekly — provides the most direct clinical comparison available. Lenders M and Brand E (2022) summarize Phase 1/2 and Phase 3 BALANCE data showing non-inferiority on eGFR stabilization over 24 months, with biomarker reductions in Gb3 and lyso-Gb3. The open-label extension demonstrated sustained efficacy.

The European Medicines Agency (EMA) and FDA have both engaged with pegunigalsidase alfa's regulatory dossier — the FDA Breakthrough Therapy designation is cited in Schiffmann R, Bichet DG et al. (2021) as reflecting the unmet need in a patient population where immunogenicity limits long-term ERT benefit. PatSnap's life sciences intelligence platform enables teams to track regulatory signals alongside patent activity in a single workflow.

For comparative effectiveness context, Ortiz A et al. (2021) describe broadly comparable renal and cardiac outcomes between agalsidase alfa and agalsidase beta despite their 5-fold dose difference — suggesting that the ERT class effect, rather than specific formulation, drives much of the observed clinical benefit. This creates an opening for pegunigalsidase alfa to differentiate on immunogenicity rather than efficacy magnitude.